Article Text

Download PDFPDF
Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis
  1. A Céspedes-Cruz1,
  2. R Gutiérrez-Suárez1,
  3. A Pistorio2,
  4. A Ravelli3,
  5. A Loy1,
  6. K J Murray4,
  7. V Gerloni5,
  8. N Wulffraat6,
  9. S Oliveira1,
  10. J Walsh7,
  11. I Calvo Penades8,
  12. M G Alpigiani9,
  13. P Lahdenne10,
  14. C Saad-Magalhães1,
  15. E Cortis11,
  16. L Lepore12,
  17. Y Kimura13,
  18. C Wouters14,
  19. A Martini3,
  20. N Ruperto1,
  21. for the Pediatric Rheumatology International Trials Organization (PRINTO)
  1. 1
    IRCCS G Gaslini, Pediatria II, Reumatologia, PRINTO, Genova, Italy
  2. 2
    IRCCS G Gaslini, Servizio di Epidemiologia e Biostatistica, Genova, Italy
  3. 3
    IRCCS G Gaslini, Pediatria II, Reumatologia and Dipartimento di Pediatria, Universitè degli Studi, Genova, Italy
  4. 4
    FRACP, Princess Margaret Hospital for Children, Rheumatology Department, Perth, Australia
  5. 5
    Istituto Gaetano Pini, Milan, Italy
  6. 6
    Wilhelmina Kinderziekenhuis, Department of Pediatric Immunology and Rheumatology, Utrecht, Netherlands
  7. 7
    Royal Alexandra Hospital, Glasgow, Scotland, UK
  8. 8
    Hospital Universitario La Fe, Valencia, Spain
  9. 9
    IRCCS G Gaslini, Clinica Pediatrica, Genova, Italy
  10. 10
    Hospital for Children and Adolescents, Helsinki University Central Hospital, Pediatric Rheumatology, Helsinki, Finland
  11. 11
    Ospedale Pediatrico Bambin Gesù, Rome, Italy
  12. 12
    Universita’ degli Studi di Trieste, Trieste, Italy
  13. 13
    Hackensack Medical Center, Hackensack, NJ, USA
  14. 14
    University Hospital Gasthuisberg, Leuven, Belgium
  1. Dr N Ruperto, IRCCS G Gaslini, Universitè di Genova, Pediatria II, Reumatologia, PRINTO, Largo Gaslini, 5, 16147 Genova, Italy; nicolaruperto{at}; or


Objectives: To examine the change in health-related quality of life (HRQOL) and its determinants in children with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX).

Methods: Patients were extracted from the PRINTO clinical trial which aimed to evaluate the efficacy and safety profile of MTX administered in standard, intermediate or higher doses (10, 15 and 30 mg/m2/week respectively). Children with polyarticular-course JIA, who were less than 18 years and had a complete HRQOL assessment were included.

Results: A total of 521 children were included. At baseline, patients with JIA showed poorer HRQOL (p<0.01) than healthy children. In 207/412 (50%) and 63 (15%) children, HRQOL values were 2 standard deviations below the mean of healthy controls in the physical and psychosocial summary scale, respectively. After 6 months of treatment with standard dose MTX, there was a statistically significant improvement in all HRQOL health concepts, particularly the physical ones. Similar improvements were observed in those who did not respond to a standard dose of MTX and were subsequently randomised to a higher dose. The presence of marked disability at baseline was associated with a fivefold increased risk of retaining poor physical health after 6 months of active treatment with standard dose MTX. Other less important determinants of retaining poor physical well-being were the baseline level of systemic inflammation, pain intensity and an antinuclear-antibody-negative status.

Conclusions: MTX treatment produces a significant improvement across a wide range of HRQOL components, particularly in the physical domains, in patients with JIA.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • AC-C and RG-S contributed equally to the paper.

  • Competing interests: None.

  • Ethics approval: The study was approved by the local ethics committee, and informed consent was obtained from parents or legal guardians.